BACKGROUND AND OBJECTIVES: Incidence of AKI in hospitalized patients with cancer is increasing, but reports are scant. The objective of this study was to determine incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a cancer center. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Cross-sectional analysis of prospectively collected data on 3558 patients admitted to the University of Texas M.D. Anderson Cancer Center over 3 months in 2006. RESULTS: Using modified RIFLE (Risk, Injury, Failure, Loss, ESRD) criteria, 12% of patients admitted to the hospital had AKI, with severity in the Risk, Injury, and Failure categories of 68%, 21%, and 11%, respectively. AKI occurred in 45% of patients during the first 2 days and in 55% thereafter. Dialysis was required in 4% of patients and nephrology consultation in 10%. In the multivariate model, the odds ratio (OR) for developing AKI was significantly higher for diabetes (OR, 1.89; 95% confidence interval [CI], 1.51-2.36), chemotherapy (OR, 1.61; 95% CI, 1.26-2.05), intravenous contrast (OR, 4.55; 95% CI, 3.51-5.89), hyponatremia (OR, 1.97; 95% CI, 1.57-2.47), and antibiotics (OR, 1.52; 95% CI, 1.15-2.02). In patients with AKI, length of stay (100%), cost (106%), and odds for mortality (4.7-fold) were significantly greater. CONCLUSION: The rate of AKI in patients admitted to a comprehensive cancer center was higher than the rate in most noncancer settings; was correlated significantly with diabetes, hyponatremia, intravenous contrast, chemotherapy, and antibiotics; and was associated with poorer clinical outcomes. AKI developed in many patients after admission. Studies are warranted to determine whether proactive measures may limit AKI and improve outcomes.
BACKGROUND AND OBJECTIVES: Incidence of AKI in hospitalized patients with cancer is increasing, but reports are scant. The objective of this study was to determine incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a cancer center. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Cross-sectional analysis of prospectively collected data on 3558 patients admitted to the University of Texas M.D. Anderson Cancer Center over 3 months in 2006. RESULTS: Using modified RIFLE (Risk, Injury, Failure, Loss, ESRD) criteria, 12% of patients admitted to the hospital had AKI, with severity in the Risk, Injury, and Failure categories of 68%, 21%, and 11%, respectively. AKI occurred in 45% of patients during the first 2 days and in 55% thereafter. Dialysis was required in 4% of patients and nephrology consultation in 10%. In the multivariate model, the odds ratio (OR) for developing AKI was significantly higher for diabetes (OR, 1.89; 95% confidence interval [CI], 1.51-2.36), chemotherapy (OR, 1.61; 95% CI, 1.26-2.05), intravenous contrast (OR, 4.55; 95% CI, 3.51-5.89), hyponatremia (OR, 1.97; 95% CI, 1.57-2.47), and antibiotics (OR, 1.52; 95% CI, 1.15-2.02). In patients with AKI, length of stay (100%), cost (106%), and odds for mortality (4.7-fold) were significantly greater. CONCLUSION: The rate of AKI in patients admitted to a comprehensive cancer center was higher than the rate in most noncancer settings; was correlated significantly with diabetes, hyponatremia, intravenous contrast, chemotherapy, and antibiotics; and was associated with poorer clinical outcomes. AKI developed in many patients after admission. Studies are warranted to determine whether proactive measures may limit AKI and improve outcomes.
Authors: Christian Fynbo Christiansen; Martin Berg Johansen; Wendy J Langeberg; Jon P Fryzek; Henrik Toft Sørensen Journal: Eur J Intern Med Date: 2011-06-08 Impact factor: 4.487
Authors: Amit Lahoti; Hagop Kantarjian; Abdulla K Salahudeen; Farhad Ravandi; Jorge E Cortes; Stefan Faderl; Susan O'Brien; William Wierda; Gloria N Mattiuzzi Journal: Cancer Date: 2010-09-01 Impact factor: 6.860
Authors: Abdulla K Salahudeen; Vikas Kumar; Niti Madan; Lianchun Xiao; Amit Lahoti; Joshua Samuels; Joseph Nates; Kristen Price Journal: Clin J Am Soc Nephrol Date: 2009-07-23 Impact factor: 8.237
Authors: John A Kellum; Ravindra L Mehta; Adeera Levin; Bruce A Molitoris; David G Warnock; Sudhir V Shah; Michael Joannidis; Claudio Ronco Journal: Clin J Am Soc Nephrol Date: 2008-01-23 Impact factor: 8.237
Authors: R A Zager; J O'Quigley; B K Zager; C E Alpers; H M Shulman; L M Gamelin; P Stewart; E D Thomas Journal: Am J Kidney Dis Date: 1989-03 Impact factor: 8.860
Authors: Betsy A Kohler; Elizabeth Ward; Bridget J McCarthy; Maria J Schymura; Lynn A G Ries; Christie Eheman; Ahmedin Jemal; Robert N Anderson; Umed A Ajani; Brenda K Edwards Journal: J Natl Cancer Inst Date: 2011-03-31 Impact factor: 13.506
Authors: Abhijat Kitchlu; Eric McArthur; Eitan Amir; Christopher M Booth; Rinku Sutradhar; Habeeb Majeed; Danielle M Nash; Samuel A Silver; Amit X Garg; Christopher T Chan; S Joseph Kim; Ron Wald Journal: J Natl Cancer Inst Date: 2019-07-01 Impact factor: 13.506
Authors: Liang Li; Alexander Chang; Stephen G Rostand; Lee Hebert; Lawrence J Appel; Brad C Astor; Michael S Lipkowitz; Jackson T Wright; Cynthia Kendrick; Xuelei Wang; Tom H Greene Journal: J Am Soc Nephrol Date: 2013-11-14 Impact factor: 10.121
Authors: Cierra N Sharp; Mark A Doll; Tess V Dupre; Parag P Shah; Marimuthu Subathra; Deanna Siow; Gavin E Arteel; Judit Megyesi; Levi J Beverly; Leah J Siskind Journal: Am J Physiol Renal Physiol Date: 2016-01-06
Authors: Edward D Siew; Sharidan K Parr; Khaled Abdel-Kader; Svetlana K Eden; Josh F Peterson; Nisha Bansal; Adriana M Hung; James Fly; Ted Speroff; T Alp Ikizler; Michael E Matheny Journal: J Am Soc Nephrol Date: 2015-08-11 Impact factor: 10.121
Authors: Ala Abudayyeh; Juhee Song; Maen Abdelrahim; Ibrahim Dahbour; Valda D Page; Shouhao Zhou; Chan Shen; Bo Zhao; Rima N Pai; Jaya Amaram-Davila; Joanna-Grace Manzano; Marina C George; Sriram Yennu; Sreedhar A Mandayam; Joseph L Nates; Alvin H Moss Journal: Am J Hosp Palliat Care Date: 2020-01-27 Impact factor: 2.500